194 related articles for article (PubMed ID: 30519148)
1. A two-step strategy for identification of plasma protein biomarkers for endometrial and ovarian cancer.
Enroth S; Berggrund M; Lycke M; Lundberg M; Assarsson E; Olovsson M; Stålberg K; Sundfeldt K; Gyllensten U
Clin Proteomics; 2018; 15():38. PubMed ID: 30519148
[TBL] [Abstract][Full Text] [Related]
2. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
3. A multiplex platform for the identification of ovarian cancer biomarkers.
Boylan KLM; Geschwind K; Koopmeiners JS; Geller MA; Starr TK; Skubitz APN
Clin Proteomics; 2017; 14():34. PubMed ID: 29051715
[TBL] [Abstract][Full Text] [Related]
4. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
5. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
7. High throughput proteomics identifies a high-accuracy 11 plasma protein biomarker signature for ovarian cancer.
Enroth S; Berggrund M; Lycke M; Broberg J; Lundberg M; Assarsson E; Olovsson M; Stålberg K; Sundfeldt K; Gyllensten U
Commun Biol; 2019; 2():221. PubMed ID: 31240259
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of differential plasma proteins levels in epithelial ovarian cancer.
Periyasamy A; Gopisetty G; Subramanium MJ; Velusamy S; Rajkumar T
J Proteomics; 2020 Aug; 226():103893. PubMed ID: 32634479
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis.
Dayyani F; Uhlig S; Colson B; Simon K; Rolny V; Morgenstern D; Schlumbrecht M
Int J Gynecol Cancer; 2016 Nov; 26(9):1586-1593. PubMed ID: 27540691
[TBL] [Abstract][Full Text] [Related]
10. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.
Xu Y; Shen Z; Wiper DW; Wu M; Morton RE; Elson P; Kennedy AW; Belinson J; Markman M; Casey G
JAMA; 1998 Aug; 280(8):719-23. PubMed ID: 9728644
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
12. Identification of Candidate Plasma Protein Biomarkers for Cervical Cancer Using the Multiplex Proximity Extension Assay.
Berggrund M; Enroth S; Lundberg M; Assarsson E; Stålberg K; Lindquist D; Hallmans G; Grankvist K; Olovsson M; Gyllensten U
Mol Cell Proteomics; 2019 Apr; 18(4):735-743. PubMed ID: 30692274
[TBL] [Abstract][Full Text] [Related]
13. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
[TBL] [Abstract][Full Text] [Related]
14. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
Lycke M; Kristjansdottir B; Sundfeldt K
Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
[TBL] [Abstract][Full Text] [Related]
15. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.
Chen X; Zhou H; Chen R; He J; Wang Y; Huang L; Sun L; Duan C; Luo X; Yan H
Clin Chim Acta; 2015 Feb; 440():57-63. PubMed ID: 25447698
[TBL] [Abstract][Full Text] [Related]
16. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.
Clarke CH; Yip C; Badgwell D; Fung ET; Coombes KR; Zhang Z; Lu KH; Bast RC
Gynecol Oncol; 2011 Sep; 122(3):548-53. PubMed ID: 21708402
[TBL] [Abstract][Full Text] [Related]
17. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
[TBL] [Abstract][Full Text] [Related]
19. Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses.
Pitta Dda R; Sarian LO; Barreta A; Campos EA; Andrade LL; Fachini AM; Campbell LM; Derchain S
BMC Cancer; 2013 Sep; 13():423. PubMed ID: 24044637
[TBL] [Abstract][Full Text] [Related]
20. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?
Montagnana M; Danese E; Ruzzenente O; Bresciani V; Nuzzo T; Gelati M; Salvagno GL; Franchi M; Lippi G; Guidi GC
Clin Chem Lab Med; 2011 Mar; 49(3):521-5. PubMed ID: 21288178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
